文献速递甲状腺疾病

人工智能在甲状腺癌诊疗中的应用

Artificial Intelligence Applications in Thyroid Cancer Care.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本文通过检索PubMed(截至2025年5月31日)综述人工智能在甲状腺癌诊疗中的高影响力研究,重点为超声评估甲状腺结节的计算机视觉应用,并涵盖颈淋巴结转移检测、数字细胞与组织病理、大语言模型等。结论认为AI有望改善诊断、降低医疗成本并实现个体化管理,但缺乏高质量独立前瞻性临床试验验证。

要点

  • 超声计算机视觉评估甲状腺结节是甲状腺AI研究最集中、最可能产生显著临床影响的方向。
  • AI应用还覆盖颈淋巴结转移检测与预测、数字细胞与组织病理、大语言模型分析非结构化数据及患者教育。
  • AI广泛临床落地的前提是高质量、独立的前瞻性临床试验验证,目前尚缺乏。

核心结论

  • AI有望改善甲状腺癌诊断、降低医疗成本并实现个体化管理。
  • 高质量、独立的前瞻性临床试验验证不足,是临床广泛采用该技术的必要条件。

研究设计与样本

  • 综述类:以「artificial intelligence thyroid cancer」检索PubMed数据库,检索截止2025年5月31日。
  • 依据技术创新性、大规模可泛化训练数据集及独立和/或前瞻性验证,筛选高影响力文献进行综述。

主要发现

  • 重点聚焦利用计算机视觉在甲状腺超声上评估甲状腺结节,该方向受研究者关注最多。
  • 亦涵盖AI检测与预测甲状腺癌颈部淋巴结转移、数字细胞与组织病理、大语言模型用于非结构化数据分析及患者教育等应用。
  • 综述还讨论了甲状腺AI技术的演进并引用最具影响力的研究。

临床怎么用

  • AI可辅助甲状腺超声结节评估及颈部淋巴结转移的检测与预测。
  • 大语言模型可用于非结构化数据分析与患者教育等临床场景。
  • 临床采用前需关注AI软件附加价值不明确及临床实施复杂性等问题。

局限性

  • 缺乏高质量、独立的前瞻性临床试验验证。
  • AI软件的附加价值尚不确定。
  • 对非甲状腺乳头状癌类型的性能未知,临床实施复杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Artificial intelligence (AI) has created tremendous opportunities to improve thyroid cancer care. EVIDENCE ACQUISITION: We used the "artificial intelligence thyroid cancer" query to search the PubMed database until May 31, 2025. We highlight a set of high-impact publications selected based on technical innovation, large generalizable training datasets, and independent and/or prospective validation of AI. EVIDENCE SYNTHESIS: We review the key applications of AI for diagnosing and managing thyroid cancer. Our primary focus is on using computer vision to evaluate thyroid nodules on thyroid ultrasound, an area of thyroid AI that has gained the most attention from researchers and will likely have a significant clinical impact. We also highlight AI for detecting and predicting thyroid cancer neck lymph node metastases, digital cyto- and histopathology, large language models for unstructured data analysis, patient education, and other clinical applications. We discuss how thyroid AI technology has evolved and cite the most impactful research studies. Finally, we balance our excitement about the potential of AI to improve clinical care for thyroid cancer with current limitations, such as the lack of high-quality, independent prospective validation of AI in clinical trials, the uncertain added value of AI software, unknown performance on non-papillary thyroid cancer types, and the complexity of clinical implementation. CONCLUSION: AI promises to improve thyroid cancer diagnosis, reduce health care costs and enable personalized management. High-quality, independent prospective validation of AI in clinical trials is lacking and is necessary for the clinical community's broad adoption of this technology.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Pozdeyev N, White SL, Bell CC, et al. Artificial Intelligence Applications in Thyroid Cancer Care. J Clin Endocrinol Metab. 2026. PMID: 40997161. doi:10.1210/clinem/dgaf530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。